DNLI earnings date and last-quarter result: next report 2026-08-10, last quarter beat, P/E -8.21. Updated 2026-07-23.
Denali Therapeutics (DNLI) Research Hub
Denali Therapeutics (DNLI) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 18.66 USD (+1.36%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -8.21, market cap 3.72B. This hub links to the full technical, earnings and options research available for DNLI.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 18.66 USD (+1.36%) |
| 52-week range | 17.33 USD – 27.3 USD |
| Trend regime | Range |
| 14-day RSI | 45 (Neutral) |
| Trailing P/E | -8.21 |
| Market cap | 3.72B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for DNLI
Covered Call on DNLI: how it works, illustrative setup around the real 18.66 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on DNLI: how it works, illustrative setup around the real 18.66 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on DNLI: how it works, illustrative setup around the real 18.66 USD price, max profit/loss, breakeven and when to use it. Educational.
DNLI technical analysis: range, last 18.66 USD, RSI 45, 52w range 17.33 USD–27.3 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is DNLI in?
Denali Therapeutics (DNLI) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is DNLI in an uptrend or downtrend?
As of 2026-10-26, DNLI is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is DNLI's trailing P/E ratio?
DNLI's trailing P/E is -8.21, with a market cap of 3.72B. See the earnings research page for full valuation detail.
When does DNLI next report earnings?
DNLI is next scheduled to report earnings on 2026-08-10.